Aktien Sensor

Vertex Pharmaceuticals has received approval for ALYFTREK, a new cystic fibrosis treatment, in Canada, expanding options for up to 60 patients.

Alnylam Pharmaceuticals has gained a positive rating from Truist Securities, citing the company’s promising pipeline and growth prospects in the treatment of human diseases.

Sartorius AG’s second-quarter revenue fell short of market expectations, raising concerns about the company’s ability to meet its full-year revenue growth target.

Pfizer’s stock price has surged 8.24% in the past month, driven by a shift in the COVID-19 vaccine landscape and the company’s strong position in the pharmaceutical industry.

Sanofi has made a $1.6 billion bid to revive its struggling stock by acquiring British biotech firm Vicebio, in a move aimed at bolstering its vaccine portfolio.

Bristol-Myers Squibb’s stock price has plummeted 24% from its 52-week high, leaving the company’s future uncertain as it navigates the challenges of generic competition and market volatility.

Novartis reports record sales for its medication Kisqali in the second quarter, despite global market uncertainty surrounding the US-China trade agreement.

IQVIA Holdings Inc reported a 5.3% year-over-year revenue increase, beating expectations and driving a significant rise in its stock price.

AstraZeneca plans to invest $50 billion in the US by 2030, creating tens of thousands of jobs and solidifying its presence in the American pharmaceutical market.

Roche Holding AG has secured key regulatory approvals for innovative products and outlined plans to modernize its capital structure, positioning the company for long-term success and growth.